The growing problem of new psychoactive substances (NPS)

Current Topics in Behavioral Neurosciences

Volumn 32, Issue , 2017, Pages 1-18

  Madras, Bertha K ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MCLEAN HOSPITAL   (United States)

Author keywords

Cathinones; New psychoactive substances; Synthetic cannabinoids

Indexed keywords

CANNABINOID; CATHINONE; PSYCHOTROPIC AGENT; PYROVALERONE; 1-PENTYL-3-(1-NAPHTHOYL)INDOLE; 4' METHYLMETHCATHINONE; ALKALOID; ALPHA-PYRROLIDINOVALEROPHENONE; CENTRAL STIMULANT AGENT; DESIGNER DRUG; INDOLE DERIVATIVE; METHAMPHETAMINE; METHYLONE; MONOMETHYLPROPION; NAPHTHALENE DERIVATIVE; PROPIOPHENONE DERIVATIVE; PYRROLIDINE DERIVATIVE; STREET DRUG;

ACUTE TOXICITY; CARDIOTOXICITY; COST BENEFIT ANALYSIS; DRUG MARKETING; EMERGENCY CARE; HEALTH CARE PERSONNEL; HEALTH HAZARD; HUMAN; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; PUBLIC POLICY; SCREENING; SOCIAL MEDIA; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; DRUG CONTROL; HALLUCINATION; INTERNET; MARKETING; MENTAL DISEASE; PSYCHOSIS; PUBLIC HEALTH; SUBSTANCE-RELATED DISORDERS; UNITED KINGDOM; UNITED STATES; VIOLENCE;

ALKALOIDS; CANNABINOIDS; CENTRAL NERVOUS SYSTEM STIMULANTS; DESIGNER DRUGS; DRUG AND NARCOTIC CONTROL; HALLUCINATIONS; HUMANS; INDOLES; INTERNET; MARKETING; MENTAL DISORDERS; METHAMPHETAMINE; NAPHTHALENES; PROPIOPHENONES; PSYCHOSES, SUBSTANCE-INDUCED; PSYCHOTROPIC DRUGS; PUBLIC HEALTH; PYRROLIDINES; SOCIAL MEDIA; STREET DRUGS; SUBSTANCE-RELATED DISORDERS; UNITED KINGDOM; UNITED STATES; VIOLENCE;

EID: 85017522447     PISSN: 18663370     EISSN: 18663389     Source Type: Book Series    
DOI: 10.1007/7854_2016_34     Document Type: Chapter

References (44)

1. Nichols DE, Fantegrossi WE (2013) Emerging designer drugs. In: Madras B, Kuhar M (eds) The effects of drug abuse on the human nervous system. Academic Press, Cambridge, MA, pp 575-596
2. Papaseit E, Farré M, Schifano F, Torrens M (2014) Emerging drugs in Europe. Curr Opin Psychiatry 27:243-250
3. Deluca P, Davey Z, Corazza O et al (2012) Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project. Prog Neuropsychopharmacol Biol Psychiatry 39:221-226
4. Brandt SD, King LA, Evans-Brown M (2014) The new drug phenomenon. Drug Test Anal 6:587-597
5. Bonar EE, Ashrafioun L, Ilgen MA (2014) Synthetic cannabinoid use among patients in residential substance use disorder treatment: prevalence, motives, and correlates. Drug Alcohol Depend 143:268-271
6. WHO (2014) http://www.who.int/medicines/areas/quality_safety/36thecddmeet/en/
7. WHO (2015) http://www.who.int/medicines/access/controlled-substances/ecdd/en/
8. Madras BK, Fahey MA, Goulet M et al (2006) Dopamine transporter (DAT) inhibitors alleviate specific parkinsonian deficits in monkeys: association with DAT occupancy in vivo. J Pharmacol Exp Ther 319:570-585
9. Meltzer PC, Butler D, Deschamps JR, Madras BK (2006) 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J Med Chem 49:1420-1432
10. WHO 5.3 (2015) http://www.who.int/medicines/access/controlled-substances/5.3_Alpha-PVP_CRev.pdf?ua=1
11. DEA (2014) Special report: synthetic cannabinoids and cathinones reported in NFLIS, 2010-2013. http://www.deadiversion.usdoj.gov/nflis/spec_rpt_CathCan_2013.pdf
12. Wood DM, Greene SL, Dargan PI (2013) Emergency department presentations in determining the effectiveness of drug control in the United Kingdom: mephedrone (4-methylmethcathinone) control appears to be effective using this model. Emerg Med J 30:70-71
13. EMCDDA (2015) New psychoactive substances in Europe: an update from the EU Early Warning System March 2015. http://www.emcdda.europa.eu/html.cfm/index44847EN.html
14. EMCDDA (2015) European Drug Report 2015: trends and developments. http://www.emcdda.europa.eu/attachements.cfm/att_239505_EN_TDAT15001ENN.pdf
15. EMCDDA (2015b) Internet and Drug Markets http://www.emcdda.europa.eu/system/files/publications/2155/TDXD16001ENN_FINAL.pdf
16. EMCDDA EU Early Warning System (2015) New psychoactive substances in Europe: an update from the EU early warning system March 2015. http://www.emcdda.europa.eu/attachements.cfm/att_235958_EN_TD0415135ENN.pdf
17. UNODC: United Nations Office of Drugs and Crime (2015) World Drug Report 2015. http://www.unodc.org/documents/wdr2015/World_Drug_Report_2015.pdf
18. DEA (2015) http://www.dea.gov/docs/2015%20NDTA%20Report.pdf
19. Johnston LD, O’Malley PM, Miech RA et al (2016) Monitoring the future national results on adolescent drug use: overview of key findings, 2015. Institute for Social Research, the University of Michigan, Ann Arbor, MI
20. Trecki J, Gerona RR, Schwartz MD (2015) Synthetic cannabinoid-related illnesses and deaths. N Engl J Med 373:103-107
21. Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979-980
22. Bonnet C, Rusz J, Megrelishvili M et al (2014) Eye movements in ephedrone-induced parkinsonism. PLoS One 9, e104784
23. Schneir A, Ly BT, Casagrande K et al (2014) Comprehensive analysis of “bath salts” purchased from California stores and the internet. Clin Toxicol (Phila) 52:651-658
24. Seely KA, Patton AL, Moran CL et al (2013) Forensic investigation of K2, Spice, and “bath salt” commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. Forensic Sci Int 233:416-422
25. Carhart-Harris RL, King LA, Nutt DJ (2011) A web-based survey on mephedrone. Drug Alcohol Depend 118:19-22
26. Corazza O, Assi S, Simonato P et al (2013) Promoting innovation and excellence to face the rapid diffusion of novel psychoactive substances in the EU: the outcomes of the ReDNet project. Hum Psychopharmacol 28:317-323
27. Baumann MH, Solis E Jr, Watterson LR et al (2014) Baths salts, spice, and related designer drugs: the science behind the headlines. J Neurosci 34:15150-15158
28. Fass JA, Fass AD, Garcia AS (2012) Synthetic cathinones (bath salts): legal status and patterns of abuse. Ann Pharmacother 46:436-441
29. Prosser JM, Nelson LS (2012) The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 8:33-42
30. NFLIS-DEA (2014) https://www.nflis.deadiversion.usdoj.gov/DesktopModules/ReportDownloads/Reports/NFLIS2014AR.pdf
31. Castaneto MS, Gorelick DA, Desrosiers NA et al (2014) Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 144:12-41
32. Gunderson EW, Haughey HM, Ait-Daoud N et al (2012) “Spice” and “K2” herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict 21:320-326
33. Seely KA, Lapoint J, Moran JH, Fattore L (2012) Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry 39:234-243
34. Hermanns-Clausen M, Kithinji J, Spehl M et al (2016) Adverse effects after the use of JWH-210 - a case series from the EU Spice II plus project. Drug Test Anal 2016 [Epub ahead of print]
35. Tait RJ, Caldicott D, Mountain D et al (2016) A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol (Phila) 54:1-13
36. Zawilska JB, Andrzejczak D (2015) Next generation of novel psychoactive substances on the horizon - A complex problem to face. Drug Alcohol Depend 157:1-17
37. Coviello L, Sohn Y, Kramer AD et al (2014) Detecting emotional contagion in massive social networks. PLoS One 12;9(3):e90315
38. Kim DA, Hwong AR, Stafford D, Hughes et al (2015) Social network targeting to maximise population behaviour change: a cluster randomised controlled trial. Lancet 386:145-153
39. Shakya HB, Christakis NA, Fowler JH (2012) Parental influence on substance use in adolescent social networks. Arch Pediatr Adolesc Med 166:1132-1139
40. YouTube https://www.youtube.com/watch?v=-WWNwW0aDh4
41. King LA, Ujváry I, Brandt SD (2014) Drug laws and the ‘derivative’ problem. Drug Test Anal 7-8:879-883
42. Jensen NH, Roth BL (2008) Massively parallel screening of the receptorome. Comb Chem High Throughput Screen 11:420-426
43. Sheffler DJ, Roth BL (2003) Salvinorin A: the “magic mint” hallucinogen finds a molecular target in the kappa opioid receptor. Trends Pharmacol Sci 24:107-109
44. Setola V, Roth BL (2005) Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on ‘fen-phen’. Expert Opin Drug Metab Toxicol 1:377-387